This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer’s disease


Wiig, E. H., Annas, P., Basun, H., Andreasen, N., Lannfelt, L., Zetterberg, H., Blennow, K., Minthon, L.


Acta Neurologica Scandinavica, Volume: 121, No.: 3, Pages.: 186-193

Year of Publication



Objectives: To explore the longitudinal stability of measures of cognition during treatment with acetylcholinesterase inhibitors (AchEI) in patients with Alzheimer’s disease (AD).; Materials and Methods: Cognitive status was measured in a cohort of 60 patients at 6 months after initiation of treatment with AchEI (baseline) and after an additional 6 months of treatment (endpoint). A Quick Test of Cognitive Speed (AQT), Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and MMSE were administered concurrently.; Results: Correlations (rho) between age and AQT processing speed were non-significant, but were significant for ADAS-Cog and Mini Mental State Examination (MMSE). AQT and ADAS-Cog means did not differ significantly between baseline and endpoint. There was a small, significant reduction in MMSE point scores. Measures of stability (Spearman’s rho) were moderate-to-high for all tests. Means for subgroups did not differ as a function of medication type.; Conclusions: AQT processing speed, ADAS-Cog, and MMSE measures proved stable during the second 6 months of treatment with AChEI.;

Bibtex Citation

@article{Wiig_2010, doi = {10.1111/j.1600-0404.2009.01160.x}, url = {}, year = 2010, month = {mar}, publisher = {Wiley-Blackwell}, volume = {121}, number = {3}, pages = {186--193}, author = {E. H. Wiig and P. Annas and H. Basun and N. Andreasen and L. Lannfelt and H. Zetterberg and K. Blennow and L. Minthon}, title = {The stability of {AQT} processing speed, {ADAS}-Cog and {MMSE} during acetylcholinesterase inhibitor treatment in Alzheimer's disease}, journal = {Acta Neurologica Scandinavica} }


acetylcholinesterase, aged, aged, 80 and over, alzheimer disease, analysis of variance, cerebrospinal fluid, cholinesterase inhibitors, drug therapy, female, humans, inhibitors, male, neuropsychological tests, peptide fragments, physiopathology, psychiatric status rating scales, tau proteins, therapeutic use

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Before and After Study

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime